These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8688762)

  • 1. Rapidly reversible increase in insulin requirement with interferon.
    Campbell S; Mclaren EH; Danesh BJ
    BMJ; 1996 Jul; 313(7049):92. PubMed ID: 8688762
    [No Abstract]   [Full Text] [Related]  

  • 2. Sudden onset of diabetic ketoacidosis during pegylated interferon alfa therapy.
    Jabr FI; Ordinario MM
    Am J Med; 2003 Aug; 115(2):158-9. PubMed ID: 12893407
    [No Abstract]   [Full Text] [Related]  

  • 3. Diabetes mellitus and interferon therapy.
    Frankart L; Lejeune D; Donckier J
    Diabet Med; 1997 May; 14(5):405. PubMed ID: 9171259
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of granulomatous hepatitis during treatment with interferon-alpha 2b.
    Propst A; Propst T; Dietze O; Kathrein H; Judmeier G; Vogel W
    Dig Dis Sci; 1995 Oct; 40(10):2117-8. PubMed ID: 7587776
    [No Abstract]   [Full Text] [Related]  

  • 5. Non-insulin-dependent diabetes mellitus developing during interferon-alpha therapy for chronic hepatitis C.
    Chedin P; Cahen-Varsaux J; Boyer N
    Ann Intern Med; 1996 Sep; 125(6):521. PubMed ID: 8779481
    [No Abstract]   [Full Text] [Related]  

  • 6. Hemolytic anemia provoked by recombinant alpha-interferon.
    Takase K; Nakano T; Hamada M; Shiraki K; Oohashi Y; Kihira T; Tameda Y
    J Gastroenterol; 1995 Dec; 30(6):795-7. PubMed ID: 8963402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sudden deafness induced by interferon-alpha in viral hepatitis C].
    Bailly F; Mattei A; Si Ahmed SN; Trepo C
    Gastroenterol Clin Biol; 1997; 21(2):157-8. PubMed ID: 9161483
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: life-threatening severe immune thrombocytopenia after alpha-interferon therapy for chronic hepatitis C infection.
    Khan HA; Khawaja FI; Mahrous AR
    Am J Gastroenterol; 1996 Apr; 91(4):821-2. PubMed ID: 8677971
    [No Abstract]   [Full Text] [Related]  

  • 9. Interferon-induced hypopituitarism.
    Concha LB; Carlson HE; Heimann A; Lake-Bakaar GV; Paal AF
    Am J Med; 2003 Feb; 114(2):161-3. PubMed ID: 12586243
    [No Abstract]   [Full Text] [Related]  

  • 10. [A case of interstitial pneumonia with chronic hepatitis C following interferon-alfa and sho-saiko-to therapy].
    Sugiyama H; Nagai M; Kotajima F; Yoshizawa A; Kamimura M; Horiuchi T; Kudo K; Kabe J; Hayashi S; Umeda N
    Arerugi; 1995 Jul; 44(7):711-4. PubMed ID: 7575138
    [No Abstract]   [Full Text] [Related]  

  • 11. Interferon-associated retinopathy in a young, insulin-dependent diabetic patient.
    Willson RL; Ross RD; Willson LM; Cohen G; Redfield TL; Gitter KA
    Retina; 2000; 20(4):413-5. PubMed ID: 10950429
    [No Abstract]   [Full Text] [Related]  

  • 12. Lupus syndrome, hypothyroidism and bullous skin lesions after interferon alfa therapy for hepatitis C in a haemodialysis patient.
    Pouthier D; Theissen F; Humbel RL
    Nephrol Dial Transplant; 2002 Jan; 17(1):174. PubMed ID: 11773492
    [No Abstract]   [Full Text] [Related]  

  • 13. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C.
    Soultati AS; Dourakis SP; Alexopoulou A; Deutsch M; Archimandritis AJ
    World J Gastroenterol; 2007 Feb; 13(8):1292-4. PubMed ID: 17451219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Onset of diabetes with high titer anti-GAD antibody after IFN therapy for chronic hepatitis.
    Shiba T; Morino Y; Tagawa K; Fujino H; Unuma T
    Diabetes Res Clin Pract; 1995 Dec; 30(3):237-41. PubMed ID: 8861464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulocytopenia after combined therapy with interferon and angiotensin- converting enzyme inhibitors: evidence for a synergistic hematologic toxicity.
    Jacquot C; Caudwell V; Belenfant X
    Am J Med; 1996 Aug; 101(2):235-6. PubMed ID: 8757368
    [No Abstract]   [Full Text] [Related]  

  • 16. [A case of ventricular tachycardia occurred during interferon therapy in chronic hepatitis C].
    Omae A; Katayama K; Kakiuchi Y; Okada N; Hijioka Y; Nagai Y; Ito Y; Hagiwara H; Kasahara A; Hayashi N
    Nihon Naika Gakkai Zasshi; 1995 Oct; 84(10):1734-5. PubMed ID: 8537730
    [No Abstract]   [Full Text] [Related]  

  • 17. [Case of hepatocellular carcinoma due to interferon therapy of chronic hepatitis C].
    Enomura H; Ogasawara M; Doi K; Endo T; Mori T; Matsuzaki O; Fujimoto Y; Takase K; Nakano T
    Nihon Naika Gakkai Zasshi; 1997 Oct; 86(10):1961-3. PubMed ID: 9445884
    [No Abstract]   [Full Text] [Related]  

  • 18. Underlying pathways for interferon risk to type II diabetes mellitus.
    Abdel-Hamid N; Jubori TA; Farhan A; Mahrous M; Gouri A; Awad E; Breuss J
    Curr Diabetes Rev; 2013 Nov; 9(6):472-7. PubMed ID: 24111619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [How should hepatitis C be monitored? Monitoring of treated hepatitis C].
    Larrey D
    Gastroenterol Clin Biol; 1997; 21(1 Pt 2):S99-110. PubMed ID: 9161521
    [No Abstract]   [Full Text] [Related]  

  • 20. Axonal neuropathy in a patient receiving interferon-alpha therapy for chronic hepatitis C.
    Tambini R; Quattrini A; Fracassetti O; Nemni R
    J Rheumatol; 1997 Aug; 24(8):1656-7. PubMed ID: 9263170
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.